← Leaderboards
Anna Lee Bruckner
Stanford University
$1,322,979
Attributed
$4,349,712
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2014–24$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,467,697 · 4
FDA$882,015 · 1
By mechanism
R33$2,779,497 · 1
R01$882,015 · 1
UG3$538,200 · 1
R13$150,000 · 2
Top collaborators
- Anita Nijhawan Haggstrom4 shared
- Anthony J Mancini3 shared
- Joyce Ming Cao Teng3 shared
- Joaquin M. Espinosa2 shared
- Emily Gurnee2 shared
- Angela Lynn Rachubinski2 shared
- Dawn H Siegel2 shared
- Wynnis L Tom2 shared
Most similar at Stanford University
Same institution · by research overlap
- Paul A Khavari$40,653,927
- Anthony E Oro$25,372,453
- Eleni Linos$7,508,257
- Matt Peter Marinkovich$8,061,995
- Alfred T Lane$1,623,978
Others in their field
Top investigators on “Prevent”
- Lawrence Corey · Fred Hutchinson Cancer Center$609,181,782
- Jeffrey P Krischer · University Of South Florida$605,511,231
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$530,065,238
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$499,311,118
- David Heimbrook · Leidos Biomedical Research, Inc.$496,394,926
Research focus
PreventInflammatoryMeetingsAffectSkinAreaDermatologyNeonatalOrganizational StructureInnovationLecturesDesignGuidelinesGeneticChildhoodFda ApprovedClinical TrialsClinical ResearchChildDermatologicConsensusBasic ScienceAdvocacy OrganizationsKnowledge Base
Grant awards (12)
JAK Inhibition in Down Syndrome$907,994
R33 · FY2024 · AR
JAK Inhibition in Down Syndrome$1,871,503
R33 · FY2023 · AR
Study of the Safety, Tolerability, and Efficacy of an iPS Cell-based Therapy for Recessive Dystrophic Epidermolysis Bullosa Delivered with a Spray on Skin Device$538,200
UG3 · FY2023 · AR
Pediatric Dermatology Research Alliance (PeDRA) Annual Conference$20,000
R13 · FY2020 · AR · contact PI
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations$86,773
R01 · FY2019 · FD
Pediatric Dermatology Research Alliance (PeDRA) Annual Conference$20,000
R13 · FY2019 · AR · contact PI
Pediatric Dermatology Research Alliance (PeDRA) Annual Conference$20,000
R13 · FY2018 · AR · contact PI
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations$397,921
R01 · FY2017 · FD
Pediatric Dermatology Research Alliance (PeDRA) Annual Conference$30,000
R13 · FY2017 · AR · contact PI
Pediatric Dermatology Research Alliance (PeDRA) Annual Conference$30,000
R13 · FY2016 · AR
Pediatric Dermatology Research Alliance (PeDRA) Annual Conference$30,000
R13 · FY2015 · AR
Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations$397,321
R01 · FY2014 · FD